Discovery oncology adoptive cell therapy

Adoptive cell therapies (ACTs) can deliver transformative approaches to patient care. Whether you are working with tumor-infiltrating lymphocytes, gene-modified T-cells expressing novel T-cell receptors, chimeric antigen receptor T-cells (CAR T) or CAR natural killer cells, we can support your discovery assessments with our breadth of experience and focused scientific expertise. Our extensive in vitro, in vivo and ex vivo services provide decisive preclinical assessment of the efficacy and safety of your CAR T-cells.